NanoViricides, Inc. (NYSE American: NNVC) announced that the Pillar Committee in Charge in the Democratic Republic of Congo has approved the company’s proposal to conduct a Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company said NV-387 is a broad-spectrum antiviral designed to target host-cell features required by viruses and is the only orally administered Ebola treatment candidate currently under consideration for clinical testing, to its knowledge.
NanoViricides said the next steps include obtaining approvals from the DRC National Ethics Committee and regulatory agency ACOREP before initiating the study. The company noted that NV-387 Oral Gummies have already received authorization in the DRC for a Phase II mpox trial and are ready for shipment. Management believes the oral formulation could offer significant advantages in resource-limited outbreak settings, where intravenous treatments can be difficult to deploy and scale.
The approval marks a critical milestone for NanoViricides as it advances its lead drug candidate NV-387, a broad-spectrum antiviral that the company plans to develop for multiple viral infections including RSV, COVID, Long COVID, Influenza, MPOX, and Ebola. The oral gummy formulation is particularly notable because it could simplify administration in remote areas without the need for cold chain logistics or trained medical personnel for IV infusions. This could dramatically increase the speed and reach of therapeutic interventions during outbreaks.
For leaders in business and technology, this development underscores the growing convergence of nanotechnology and antiviral drug development. NanoViricides’ platform, based on TheraCour nanomedicine technology, aims to create targeted nanoviricide drugs that can be adapted across different viruses. The company’s ability to secure regulatory clearance in a resource-constrained setting like the DRC also suggests that regulators are recognizing the potential of novel delivery mechanisms to address urgent public health needs.
The broader implication for the industry is that oral antiviral gummies could become a new standard for outbreak preparedness, reducing dependence on injectable drugs that require significant infrastructure. For investors and business strategists, NanoViricides’ progress may signal a shift toward more patient-friendly and scalable antiviral therapies, potentially influencing future pandemic response strategies. The company’s ongoing work on NV-387 for mpox and other viral diseases also points to a platform approach that could be leveraged for multiple revenue streams.
It is important to note that drug development remains a lengthy and capital-intensive process. As with any pharmaceutical candidate, there is no assurance that NV-387 will demonstrate sufficient safety and efficacy in clinical trials to secure regulatory approval. However, the DRC’s approval for a Phase II Ebola trial represents a concrete step forward and provides a near-term catalyst to watch.
For more details on the announcement, visit the company’s newsroom at https://nnw.fm/NNVC.
